1 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Drug-resistant Tuberculosis: new trials by email Literature Review of Drug-resistant Tuberculosis trials Research Report on Drug-resistant Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort BLMZ - Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Beijing Chest Hospital | 120 | 2025-12-01 | 2025-12-08 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
Tuberculosis, Multidrug-Resistant (3) · Tuberculosis, Pulmonary (3) · Tuberculosis (2)
Actinomycetales Infections (3) · Bacterial Infections (3) · Bacterial Infections and Mycoses (3) · Gram-Positive Bacterial Infections (3) · Infections (3) · Lung Diseases (3) · Mycobacterium Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Tuberculosis (1)
bedaquiline (2) · Clofazimine (1) · Ethambutol (1) · Fumigant 93 (1) · Isoniazid (1) · Levofloxacin (1) · Linezolid (1) · Moxifloxacin (1) · OPC-67683 (1) · Pyrazinamide (1) · Rifampin (1) · pretomanid (1)
Beijing Chest Hospital (1) · Global Alliance for TB Drug Development (1) · Huashan Hospital (1)
China (2) · Brazil (1) · Georgia (1) · Malaysia (1) · Philippines (1) · Russia (1) · South Africa (1) · Tanzania (1) · Uganda (1)
Morounfolu Olugbosi, MD MSc (1)